{"nctId":"NCT01135069","briefTitle":"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A MicroÂ® and Placebo","startDateStruct":{"date":"2009-10"},"conditions":["Acne"],"count":480,"armGroups":[{"label":"Generic","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tretinoin microsphere 0.1%"]},{"label":"Brand","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo microsphere gel"]}],"interventions":[{"name":"Tretinoin microsphere 0.1%","otherNames":[]},{"name":"Brand Retin-A Micro tretinoin microsphere gel 0.1%","otherNames":["Retin-A Micro"]},{"name":"placebo microsphere gel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Normal, healthy male and female children and adult\n* Written and verbal informed consent must be obtained. Patients age 12 to 17 (inclusive) must sign an assent for the study and a parent or a legal guardian must sign the informed consent.\n* Women of child-bearing potential must be non-pregnant and non-nursing, and must be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study.\n* Able to refrain from the use of all other topical acne medications or antibiotics during the treatment period.\n* Considered reliable and capable of understanding their responsibility and role in the study.\n\nExclusion Criteria:\n\n* Significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.\n* Abnormal pre-existing skin condition which might affect the normal course of acne vulgaris (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders).\n* Use topical acne therapy during the two week period prior to study initiation.\n* Use of systemic retinoid treatment within six months prior to study initiation.\n* Pregnant or breast-feeding.\n* Serious psychological illness.\n* Participation in any clinical research study during the 30 day period preceding study initiation.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Improvement in Acne","description":"Counting of acne lesions both inflammatory and non-inflammatory","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-74","spread":".05"},{"groupId":"OG001","value":"-76","spread":".04"},{"groupId":"OG002","value":"-58","spread":".03"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":205},"commonTop":["Irritation"]}}}